Cancer drugmaker Turning Point Therapeutics has tapped investment banker Yi Larson as the company’s chief financial officer.
Previously Larson was the managing director of health care investment banking at Goldman Sachs. She held the role for a dozen years.
“Yi brings an important new dimension to our growing team from her experience advising biotechnology companies through more than $100 billion in financing and strategic transactions,” said Athena Countouriotis, CEO of Turning Point.
The San Diego Business Journal this week profiled Turning Point on the heels of the company’s $175.2 million initial public offering.